HK1049338B - 糖原合成酶激酶3的二環抑制劑 - Google Patents

糖原合成酶激酶3的二環抑制劑

Info

Publication number
HK1049338B
HK1049338B HK03101537.5A HK03101537A HK1049338B HK 1049338 B HK1049338 B HK 1049338B HK 03101537 A HK03101537 A HK 03101537A HK 1049338 B HK1049338 B HK 1049338B
Authority
HK
Hong Kong
Prior art keywords
treatment
gsk3
glycogen synthase
synthase kinase
disorders
Prior art date
Application number
HK03101537.5A
Other languages
English (en)
Other versions
HK1049338A1 (en
Inventor
M Nuss John
A Zhou Xiaohui
Original Assignee
Novartis Vaccines & Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostics Inc filed Critical Novartis Vaccines & Diagnostics Inc
Publication of HK1049338A1 publication Critical patent/HK1049338A1/xx
Publication of HK1049338B publication Critical patent/HK1049338B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK03101537.5A 1999-12-17 2003-02-28 糖原合成酶激酶3的二環抑制劑 HK1049338B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17240399P 1999-12-17 1999-12-17
PCT/US2000/034049 WO2001044246A1 (en) 1999-12-17 2000-12-14 Bicyclic inhibitors of glycogen synthase kinase 3

Publications (2)

Publication Number Publication Date
HK1049338A1 HK1049338A1 (en) 2003-05-09
HK1049338B true HK1049338B (zh) 2005-10-21

Family

ID=22627574

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03101537.5A HK1049338B (zh) 1999-12-17 2003-02-28 糖原合成酶激酶3的二環抑制劑

Country Status (11)

Country Link
US (2) US6800632B2 (zh)
EP (1) EP1240168B1 (zh)
JP (1) JP2003516991A (zh)
KR (1) KR100711817B1 (zh)
CN (1) CN100335479C (zh)
AT (1) ATE303383T1 (zh)
AU (1) AU784748B2 (zh)
DE (1) DE60022388T2 (zh)
ES (1) ES2246927T3 (zh)
HK (1) HK1049338B (zh)
WO (1) WO2001044246A1 (zh)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1240168B1 (en) * 1999-12-17 2005-08-31 Chiron Corporation Bicyclic inhibitors of glycogen synthase kinase 3
KR100868841B1 (ko) * 2001-09-21 2008-11-14 사노피-아벤티스 치환된2-피리디닐-6,7,8,9-테트라히드로피리미도[1,2-ａ]피리미딘-4-온 및7-피리디닐-2,3-디히드로이미다조[1,2-ａ]피리미딘-5(1ｈ)온유도체
EP1295885A1 (en) * 2001-09-21 2003-03-26 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives
ES2250721T3 (es) 2001-09-21 2006-04-16 Sanofi-Aventis Derivados de 2-pirimidinil-6,7,8,9-tetrahidropirimido(1,2-a)pirimidin-4-ona y 7-pirimidinil-2,3-dihidroimidazo(1,2-a)pirimidin-5(1h)ona sustituidos para enfermedades neurodegenerativas.
EP1295884A1 (en) * 2001-09-21 2003-03-26 Sanofi-Synthelabo 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives
EP2198867A1 (en) 2001-12-07 2010-06-23 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as GSK-3 inhibitors
CN1630863B (zh) * 2002-02-11 2010-06-09 诺华疫苗和诊断公司 人gsk3的结晶方法及其新的晶体结构
JP2005525362A (ja) * 2002-03-01 2005-08-25 カイロン コーポレイション 虚血の処置のための方法および組成物
EP1552842A1 (en) 2002-06-07 2005-07-13 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
US7250443B2 (en) 2002-08-23 2007-07-31 Chiron Corporation Pyrrole based inhibitors of glycogen synthase kinase 3
CA2531232A1 (en) 2003-07-16 2005-02-10 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
CA2542329A1 (en) * 2003-10-16 2005-04-28 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
DE102004020908A1 (de) * 2004-04-28 2005-11-17 Grünenthal GmbH Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen
US7745451B2 (en) 2005-05-04 2010-06-29 Renovis, Inc. Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and dysfunctions
CA2612475C (en) * 2005-06-20 2015-07-28 Decode Genetics Ehf. Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitus
WO2007016189A2 (en) * 2005-07-28 2007-02-08 University Of Massachusetts Glucose transport-related genes, polypeptides, and methods of use thereof
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1790649A1 (en) * 2005-11-21 2007-05-30 Sanofi-Aventis Substituted bicyclic pyrimidone derivatives
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP1991212A1 (en) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007225088B2 (en) * 2006-03-13 2012-09-13 Kyorin Pharmaceutical Co., Ltd Aminoquinolones as GSK-3 inhibitors
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ES2446269T3 (es) * 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
JP2010159210A (ja) * 2007-04-26 2010-07-22 Dainippon Sumitomo Pharma Co Ltd 縮合複素環誘導体
US8263547B2 (en) 2008-05-28 2012-09-11 Massachusetts Institute Of Technology DISC-1 pathway activators in the control of neurogenesis
WO2010053825A1 (en) 2008-10-29 2010-05-14 Janssen Pharmaceutica Nv 2-aminopyrimidine compounds as serotonin receptor modulators
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB0907284D0 (en) 2009-04-28 2009-06-10 Queen Mary & Westfield College Compounds for inducing cellular apoptosis
JP2013032290A (ja) * 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2012018639A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
WO2012018638A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
CN102827160B (zh) * 2011-06-16 2015-11-18 上海阳帆医药科技有限公司 PI3K或PI3K/m-TOR通路抑制剂及其在药学中的用途
EP2554662A1 (en) 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
EP3249054A1 (en) 2012-12-20 2017-11-29 Biomatrica, INC. Formulations and methods for stabilizing pcr reagents
EP3007556B1 (en) 2013-06-13 2020-05-20 Biomatrica, INC. Cell stabilization
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
ES2891555T3 (es) 2014-06-10 2022-01-28 Biomatrica Inc Estabilización de trombocitos a temperaturas ambiente
EP4242628A3 (en) 2015-12-08 2023-11-08 Biomatrica, INC. Reduction of erythrocyte sedimentation rate
EP3231434A1 (en) 2016-04-14 2017-10-18 Fundacio Centre de Regulacio Genomica Method of treatment of parkinsonism
RU2663913C1 (ru) * 2016-11-17 2018-08-13 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Твердая лекарственная форма антидиабетического препарата на основе N-замещенного производного амринона - ингибитора киназы гликогенсинтазы
WO2018217766A1 (en) 2017-05-22 2018-11-29 Whitehead Institute For Biomedical Research Kcc2 expression enhancing compounds and uses thereof
JP2022520671A (ja) 2019-02-08 2022-03-31 フリークエンシー・セラピューティクス・インコーポレイテッド 耳障害を治療するためのバルプロ酸化合物及びｗｎｔ作動薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA764962A (en) * 1962-03-22 1967-08-08 Ohnacker Gerhard Pyrido-pyrimidines
AU7692696A (en) * 1995-12-01 1997-06-27 Novartis Ag Heteroaryl derivatives
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
DE69919707T2 (de) * 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
EP1240168B1 (en) * 1999-12-17 2005-08-31 Chiron Corporation Bicyclic inhibitors of glycogen synthase kinase 3

Also Published As

Publication number Publication date
US6800632B2 (en) 2004-10-05
DE60022388T2 (de) 2006-06-14
WO2001044246A8 (en) 2001-10-25
CN100335479C (zh) 2007-09-05
DE60022388D1 (de) 2005-10-06
US20010044436A1 (en) 2001-11-22
AU2580201A (en) 2001-06-25
EP1240168B1 (en) 2005-08-31
KR20020061647A (ko) 2002-07-24
EP1240168A1 (en) 2002-09-18
AU784748B2 (en) 2006-06-08
HK1049338A1 (en) 2003-05-09
WO2001044246A1 (en) 2001-06-21
ATE303383T1 (de) 2005-09-15
ES2246927T3 (es) 2006-03-01
JP2003516991A (ja) 2003-05-20
US20030008866A1 (en) 2003-01-09
KR100711817B1 (ko) 2007-05-02
CN1434824A (zh) 2003-08-06

Similar Documents

Publication Publication Date Title
HK1049338A1 (en) Bicyclic inhibitors of glycogen synthase kinase 3.
PT1237880E (pt) Inibidores baseados em pirazina da cinase 3 da glicogénio sintase
AU2003268184A1 (en) Pyrrole based inhibitors of glycogen synthase kinase 3
AU4956699A (en) Inhibitors of glycogen synthase kinase 3
WO2002020495A3 (en) Inhibitors of glycogen synthase kinase 3
IL161829A (en) 1,2,4 - thiadiazole derivatives, some of which are novel and pharmaceutical compositions comprising the same for treating disorders mediated by melanocortin receptor modulators
WO2004022544A8 (fr) Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
WO2007041365A3 (en) 3-cyclyl-2- (4-sulfamo yl-phenyl) -n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes
EP1808177A3 (en) Methods of treatment of mitochondrial disorders
IL146482A (en) Tek antagonists
WO2000006085A3 (en) Compounds and methods
EP1201268A3 (en) Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors
AU2002307049A1 (en) Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
WO2006034491A3 (en) Phenyl-substituted quinoline and quinazoline compounds for the treatment of diabetes
WO2004045557A3 (en) Novel lapachone compounds and methods of use thereof
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2003020280A3 (en) Compositions and use thereof in the treatment of cancer
WO2002072584A3 (en) Tetrahydro-pyrazino (1,2-a) indoles for the treatment of central nervous disorders
GB0420831D0 (en) Novel compounds
EP1032556A4 (en) PHARMACEUTICALLY EFFECTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
WO2000047547A3 (en) Cycloalkyl amine compounds and uses thereof
WO2004032864A3 (en) X-nitro compounds, pharmaceutical compositions thereof and uses therof
WO2005106489A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 5 (ccr5)
GB2430365B (en) High-purity texaphyrin metal complexes
WO2004026846A8 (en) Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20111214